Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Arcutis Biotherapeutics, Inc. ARQT
$10.27
-$0.53 (-5.17%)
На 18:01, 12 мая 2023
+328.43%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
917498857.00000000
-
week52high
27.40
-
week52low
10.05
-
Revenue
3686000
-
P/E TTM
-3
-
Beta
0.45053400
-
EPS
-5.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 02 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 02 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 07 июн 2022 г. |
| Morgan Stanley | Overweight | Overweight | 10 мая 2022 г. |
| Mizuho | Buy | Buy | 07 апр 2022 г. |
| Needham | Buy | 07 сент 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 27 сент 2022 г. |
| Morgan Stanley | Overweight | Overweight | 04 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 13 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Watanabe Todd Franklin | D | 377907 | 382 | 01 февр 2023 г. |
| Watanabe Todd Franklin | D | 378289 | 618 | 01 февр 2023 г. |
| Welgus Howard G. | D | 31958 | 8500 | 17 янв 2023 г. |
| Welgus Howard G. | D | 165825 | 8500 | 17 янв 2023 г. |
| Welgus Howard G. | A | 174325 | 8500 | 17 янв 2023 г. |
| Burnett Patrick | D | 41564 | 1475 | 03 янв 2023 г. |
| Watanabe Todd Franklin | D | 378907 | 1000 | 07 дек 2022 г. |
| Matsuda Masaru | D | 19535 | 1720 | 21 ноя 2022 г. |
| Matsuda Masaru | A | 21255 | 4875 | 18 ноя 2022 г. |
| Welgus Howard G. | D | 40458 | 1020 | 15 ноя 2022 г. |
Новостная лента
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study
Zacks Investment Research
16 ноя 2022 г. в 12:02
Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 02:36
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Eric McIntyre - Head, IR Todd Watanabe - President, CEO & Director Kenneth Lock - Chief Commercial Officer Patrick Burnett - SVP & Chief Medical Officer Scott Burrows - CFO & Principal Accounting Officer Conference Call Participants Kenneth Cacciatore - Cowen Vikram Purohit - Morgan Stanley Louise Chen - Cantor Fitzgerald Serge Belanger - Needham & Company Seamus Fernandez - Guggenheim Securities Gregory Fraser - Truist Securities Uy Ear - Mizuho Group Operator Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. Q3 2022 Earnings Conference Call.
Arcutis to Present at Upcoming Investor Conference
GlobeNewsWire
11 ноя 2022 г. в 08:00
WESTLAKE VILLAGE, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
08 ноя 2022 г. в 18:48
Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcutis to Report Third Quarter Financial Results
GlobeNewsWire
25 окт 2022 г. в 16:05
WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 5:00 p.m. ET on Tuesday, November 8, 2022, to report its third quarter financial results.